Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||92%|
|1 Day Vol Adjusted Return||0.7|
|1 Month Vol Adjusted Return||-4.0|
|3 Month Vol Adjusted Return||-2.4|
|6 Month Vol Adjusted Return||-9.3|
|20 Days SMA Price ZScore||-0.1|
|50 Days SMA Price ZScore||-0.6|
|12 -26 Days PPO||-4.0|
|1 Month Average Short Volume Ratio||40.6|
|1 Day Volume Change ZScore||-0.7|
|1 Month Daily Vol||4.1|
REDWOOD CITY, Calif., October 20, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors.
REDWOOD CITY, Calif., October 08, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after market close on Thursday, November 4, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
REDWOOD CITY, Calif., October 05, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE) study, a 1,000-patient prospective, observational, multi-center study designed to evaluate the performance of its Guardant Reveal™ liquid biopsy test to predict cancer recurrence after curative intent treatment, across 11 solid tumor types.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Shares of healthcare company Guardant Health (NASDAQ: GH) are down 14.2% as of mid-session today on the heels of unconfirmed reports that it's interested in acquiring peer and indirect rival NeoGenomics (NASDAQ: NEO). Only citing "people familiar with the matter," Bloomberg reported on Friday that disease diagnostics Guardant Health is considering an acquisition of cancer-testing specialist NeoGenomics. Although neither NeoGenomics nor Guardant Health has confirmed they're in such discussions,...
Gainers Biomerica, Inc. (NASDAQ: BMRA) shares climbed 38.3% to $6.23. Biomerica entered into a Supplier Agreement with Walmart to sell its EZ Detect colorectal disease screening test within the Walmart retail system. Progenity, Inc. (NASDAQ: PROG) gained 23% to $1.87 after jumping over 40% on Thursday. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) climbed 21.3% to $42.52 following data from Merck & Co's investigational oral antiviral molnupiravir, which boosted sentiment for Atea Pharmaceutical's AT